Last edition
News about
Alkem Reports Record FY26 EBITDA as Revenue Grows 13.5%; Q4 Profit Before Tax Rises 40.7 Percent
Alkem Laboratories posted its highest-ever EBITDA in FY26, driven by strong growth in domestic and international businesses, improved operating leverage, and disciplined cost management. The company also reported robust fourth-quarter performance, with revenue rising 14.6 percent and PBT before exceptional items increasing 40.7 percent YoY.
US FDA Grants Priority Review to Zydus Therapeutics' Saroglitazar for Primary Biliary Cholangitis
Zydus Therapeutics has received US FDA Priority Review (PR) for its New Drug Application (NDA) for saroglitazar in the treatment of Primary Biliary Cholangitis (PBC), supported by phase 3 EPICS-III trial results demonstrating significant biochemical response, with detailed data to be presented at the EASL Congress 2026.
Travere Therapeutics Receives USPTO Patent Allowance for Filspari Use in IgA Nephropathy
Travere Therapeutics has secured a Notice of Allowance from the USPTO for a patent application covering specific methods of using Filspari (sparsentan) in the treatment of IgA nephropathy, strengthening its rare kidney disease portfolio.
ReST Therapeutics Receives US FDA IND Clearance for RST-101 in Early PTSD Treatment
ReST Therapeutics has received US FDA acceptance of its Investigational New Drug (IND) application for RST-101, enabling the initiation of a first-in-human clinical trial evaluating a novel early intervention approach for the treatment of post-traumatic stress disorder.
Aphios Corporation has received a Notice of Allowance from the USPTO for a divisional patent application covering novel Bryoid compositions and manufacturing methods aimed at advancing therapies for neurodegenerative diseases, HIV latency and cancer.
Parse Biosciences and bit.bio have announced a strategic alliance to develop a comprehensive transcription factor-driven cell identity map, leveraging advanced single-cell sequencing and cell programming technologies to improve predictive drug discovery and scalable therapeutic research.
Pfizer and Innovent Biologics Partner to Advance Global Oncology Drug Development
Pfizer and Innovent Biologics have entered a global strategic collaboration to develop innovative oncology medicines, combining 12 discovery and early-stage programs to accelerate cancer drug development through shared research, clinical development, and commercialisation efforts.
FDA Grants Priority Review to Sanofi's Venglustat for Type 3 Gaucher Disease
Sanofi’s brain-penetrant investigational therapy venglustat has received FDA priority review after phase 3 data demonstrated positive efficacy and safety outcomes in patients with type 3 Gaucher disease.
IMFINZI from AstraZeneca has received US approval in combination with BCG for BCG-naïve, high-risk non-muscle-invasive bladder cancer, supported by Phase III POTOMAC trial data showing a 32 percent reduction in the risk of disease recurrence, progression, or death after one year of IMFINZI added to BCG vs. BCG alone.
GSK Reports Positive Phase 3 Results for Bepirovirsen in Chronic Hepatitis B Treatment
GSK’s investigational antisense oligonucleotide bepirovirsen demonstrated statistically significant functional cure rates in chronic hepatitis B patients, offering a potential alternative to lifelong antiviral therapy.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy